Why the study?
With increasing prescription rates of oral anticoagulants, concerns regarding major bleeding risks in non-valvular atrial fibrillation patients are rising, prompting evaluation of prescription trends, efficacy, and safety in Korea.
Do DOACs improve efficacy and safety compared to warfarin in elderly patients with non-valvular atrial fibrillation?
Do DOACs improve efficacy and safety compared to warfarin in elderly patients with non-valvular atrial fibrillation?
In 2015 in Korea, warfarin remained the most commonly prescribed oral anticoagulant (64%) for elderly patients with non-valvular atrial fibrillation, followed by rivaroxaban and dabigatran.
OAC trends in Korean NVAF may guide local prescribing; leaves open comparative safety questions versus trials.
Objective: The prescription rates for oral anticoagulants (OACs) are increasing, and concerns for the risk of major bleeding in non-valvular atrial fibrillation (NVAF) patients are also on the rise. This study aimed to analyze the prescription trends, efficacy and safety of OACs such as warfarin and direct-acting OACs (DOACs) in patients with NVAF in Korea. Methods: We conducted a retrospective study using the Health Insurance Review & Assessment Service data (2015). Patients were divided into two groups based on the type of anticoagulant taken: warfarin and DOAC. We evaluated use of OACs and their clinical outcomes. The efficacy outcome was defined as the incidence of stroke or systemic embolism and the safety outcome was major bleeding. Results: In this study, 2,840 patients used warfarin (64.0%), 936 patients used rivaroxaban (21.1%), and 659 patients used dabigatran (14.9%). The mean age was 75 years.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: